| Title： | Clinical practice guideline for neoadjuvant therapy in early-stage breast cancer (CSBrS-Guideline-23) |
| Edition： | Original |
| Classification： | Standard guideline |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | Clinicians specializing in breast diseases in China. |
| Evidence classification method： | The level of evidence grading system was developed by referring to the GRADE system combined with findings in clinical studies in China. The levels are classified as Category I, II, III, and IV to quantify the evaluation of the reliability of the evidence by experts on the compiling committees. To make these guidelines accessible in clinical practice in China, the expert panel preferentially selected Category I and II evidence, as indicated in the guideline evaluation system |
| Development unit： | Chinese Society of Breast Surgery |
| Registration time: | 2022-01-23 |
| Registration number： | IPGRP-2022CN044 |
| Purpose of the guideline: | There has been widespread consensus that neoadjuvant therapy can bring clinical benefits in early breast cancer. The purpose and significance of neoadjuvant therapy have also been enriched, including more indications, treatment options and therapeutic evaluation. The Chinese Society of Breast Surgery organized related experts to discuss the neoadjuvant therapy of breast cancer, and evaluated the relevant evidence with reference to the GRADE system, aiming to provide reference for China's breast surgeons. |
